



SUGGESTED FORMULA

Lidocaine Hydrochloride 4%, Epinephrine Hydrochloride 0.05%, Tetracaine Hydrochloride 0.5% Gel

Version number: 1.0

Quantity: 100gm

Lidocaine HCl, USP (LI103)	4gm
Epinephrine HCl, USP (EP130)	0.05gm
Tetracaine HCl, USP (TE128)	0.5gm
Ascorbic Acid, USP (AS102)	1.7gm
Propylene Glycol, USP (PR130)	0mL
Plasticized Ointment Base (P3692)	Q.S. 100gm

SUGGESTED COMPOUNDING PROCEDURES

1. Calculate the required amount of each ingredient
2. Accurately weigh and measure each ingredient
3. Mix dry ingredients with enough Propylene Glycol to form a smooth paste
4. Incorporate Plasticized Ointment Base geometrically and mix until uniform
5. Package in syringes that can be used to accurately measure a dose
6. Suggested quality assessments:
 - a. Uniform paste with no lumps
 - b. Color
 - c. Label (s)- auxiliary labels (external use), storage, BUD

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date.

It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date should be assigned base on the current USP 795 Guidelines

Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment. Use safety enclosures (hoods) when weighing and mixing.

4/18 JD